公开(公告)号：US20220280636A1

公开(公告)日：2022-09-08

申请号：US17626206

申请日：2020-07-14

申请人： Arthur FRIDMAN ,  Jennifer Dawn GALLI ,  Dai WANG ,  Lan ZHANG ,  Merck Sharp & Dohme Corp.

发明人： Arthur Fridman ,  Jennifer Dawn Galli ,  Dai Wang ,  Lan Zhang

IPC分类号： A61K39/245 ,  C12N7/00

摘要： The disclosure relates to HSV glycoprotein E antigenic peptide constructs and HSV protein vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. The present invention directed to immunogenic polypeptides of use for a vaccine against Herpes Simplex Vims (HSV). The polypeptides are glycoprotein E peptides that are mutated to reduce their binding to antibody Fc domain.

公开(公告)号：US20160130327A1

公开(公告)日：2016-05-12

申请号：US14897374

申请日：2014-06-09

申请人： Tong-Ming FU ,  Dai WANG ,  Zhiqiang AN

发明人： Tong-Ming Fu ,  Dai Wang ,  Zhiqiang An

IPC分类号： C07K16/08

CPC分类号： C07K16/088 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q1/70

摘要： The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.

摘要翻译： 本发明涉及特异性结合并优选中和人巨细胞病毒（CMV）的抗原结合蛋白，包括但不限于单克隆抗体及其抗原结合片段。 本发明还包括已经人源化的抗原结合蛋白。 本发明的抗原结合蛋白可用作治疗和/或预防有需要的患者的CMV感染的治疗剂。

公开(公告)号：US20150307850A1

公开(公告)日：2015-10-29

申请号：US14649669

申请日：2013-12-04

申请人： Tong-ming FU ,  Dai WANG ,  Danilo CASIMIRO ,  Daniel FREED ,  Fengsheng LI ,  MERCK SHARP & DOHME CORP.

发明人： Tong-Ming Fu ,  Dai Wang ,  Danilo Casimiro ,  Daniel C. Freed ,  Fengsheng Li

IPC分类号： C12N7/00 ,  A61K39/245 ,  C07K14/005

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/21 ,  A61K39/245 ,  A61K2039/5256 ,  C07K14/005 ,  C12N15/86 ,  C12N2710/16121 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2710/16141 ,  C12N2710/16152 ,  C12N2710/16162 ,  C12N2740/16234

摘要： The present invention relates to a cytomegalovirus (CMV) which has been recombinantly altered to express a heterologous polypeptide and to allow for external control of viral replication. The heterologous polypeptide may be a polypeptide of interest such as an antigen, antibody or immune modulator. The CMV vectors of the invention are replication defective, or chemically controllable replication capable, or replication competent. The present invention also relates to uses of the CMV vectors such as inducing an immune response to an antigen or expressing an antibody or immune modulator in vivo. Compositions comprising the CMV expressing the heterologous polypeptide are also encompassed by the present invention.

摘要翻译： 本发明涉及重组改变以​​表达异源多肽并允许外部控制病毒复制的巨细胞病毒（CMV）。 异源多肽可以是感兴趣的多肽，例如抗原，抗体或免疫调节剂。 本发明的CMV载体是复制缺陷的，或具有化学上可控的复制能力或复制能力的。 本发明还涉及CMV载体的用途，例如在体内诱导对抗原的免疫应答或表达抗体或免疫调节剂。 包含表达异源多肽的CMV的组合物也包括在本发明中。

公开(公告)号：US11160860B2

公开(公告)日：2021-11-02

申请号：US16607412

申请日：2018-04-25

申请人： Merck Sharp & Dohme Corp. ,  Dai Wang ,  Lan Zhang

发明人： Dai Wang ,  Lan Zhang

IPC分类号： A61K39/245 ,  A61P31/22 ,  C07K14/005 ,  C12N7/00

摘要： HSV glycoprotein B-VSV-G1 fusion proteins and variants thereof, HSV glycoprotein C antigenic peptide constructs and variants thereof, HSV immunogenic compositions and protein vaccines including the peptide constructs, and HSV DNA vaccines encoding the amino acid sequence of the peptide constructs, as well as methods of using the vaccines and compositions comprising the vaccines.

公开(公告)号：US20200069792A1

公开(公告)日：2020-03-05

申请号：US16607412

申请日：2018-04-25

申请人： Dai WANG ,  Lan ZHANG ,  Merck Sharp & Dohme Corp.

发明人： Dai Wang ,  Lan Zhang

IPC分类号： A61K39/245 ,  C12N7/00 ,  A61P31/22 ,  C07K14/005

摘要： The disclosure relates to HSV glycoprotein B and HSV glycoprotein C antigenic peptide constructs, HSV protein vaccines, and HSV DNA vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

公开(公告)号：US20120226023A1

公开(公告)日：2012-09-06

申请号：US13409987

申请日：2012-03-01

申请人： Thomas Shenk ,  Dai Wang

发明人： Thomas Shenk ,  Dai Wang

IPC分类号： C07K16/08 ,  C07K17/00 ,  C12N5/10

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/505 ,  C07K14/005 ,  C07K16/085 ,  C07K16/088 ,  C07K2317/76 ,  C12N7/00 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12Q1/025 ,  G01N2500/04

摘要： Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

摘要翻译： 公开了用于保护和治疗人巨细胞病毒（CMV）的免疫原性组合物和预防或治疗性疫苗。 描述了包含包含pUL128或pUL130的人CMV蛋白复合物的亚单位疫苗和包含至少一种编码包含pUL128或pUL130的CMV蛋白质复合物的核酸的核酸疫苗。 还公开了对包含pUL128或pUL130的CMV蛋白质复合物具有反应性的治疗性抗体以及用于筛选抑制上皮和内皮细胞的CMV感染的化合物的方法，用于免疫CMV感染的受试者的方法，用于确定中和抗体的能力的方法 抑制除成纤维细胞以外的细胞类型的CMV感染，以及减少CMV感染的方法。

公开(公告)号：US20110200633A1

公开(公告)日：2011-08-18

申请号：US12766611

申请日：2010-04-23

申请人： Thomas Shenk ,  Dai Wang

发明人： Thomas Shenk ,  Dai Wang

IPC分类号： A61K39/245 ,  A61K39/385 ,  A61P31/22

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/505 ,  C07K14/005 ,  C07K16/085 ,  C07K16/088 ,  C07K2317/76 ,  C12N7/00 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12Q1/025 ,  G01N2500/04

摘要： Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

摘要翻译： 公开了用于保护和治疗人巨细胞病毒（CMV）的免疫原性组合物和预防或治疗性疫苗。 描述了包含包含pUL128或pUL130的人CMV蛋白复合物的亚单位疫苗和包含至少一种编码包含pUL128或pUL130的CMV蛋白质复合物的核酸的核酸疫苗。 还公开了对包含pUL128或pUL130的CMV蛋白质复合物具有反应性的治疗性抗体以及用于筛选抑制上皮和内皮细胞的CMV感染的化合物的方法，用于免疫CMV感染的受试者的方法，用于测定中和抗体的能力的方法 抑制除成纤维细胞以外的细胞类型的CMV感染，以及减少CMV感染的方法。

公开(公告)号：US07704510B2

公开(公告)日：2010-04-27

申请号：US11810578

申请日：2007-06-06

申请人： Thomas Shenk ,  Dai Wang

发明人： Thomas Shenk ,  Dai Wang

IPC分类号： A61K39/245

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/505 ,  C07K14/005 ,  C07K16/085 ,  C07K16/088 ,  C07K2317/76 ,  C12N7/00 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12Q1/025 ,  G01N2500/04

摘要： Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

摘要翻译： 公开了用于保护和治疗人巨细胞病毒（CMV）的免疫原性组合物和预防或治疗性疫苗。 描述了包含包含pUL128或pUL130的人CMV蛋白复合物的亚单位疫苗和包含至少一种编码包含pUL128或pUL130的CMV蛋白质复合物的核酸的核酸疫苗。 还公开了对包含pUL128或pUL130的CMV蛋白质复合物具有反应性的治疗性抗体以及用于筛选抑制上皮和内皮细胞的CMV感染的化合物的方法，用于免疫CMV感染的受试者的方法，用于测定中和抗体的能力的方法 以抑制除成纤维细胞以外的细胞类型的人CMV感染，以及减少CMV感染的方法。

公开(公告)号：US20080187545A1

公开(公告)日：2008-08-07

申请号：US11810578

申请日：2007-06-06

申请人： Thomas Shenk ,  Dai Wang

发明人： Thomas Shenk ,  Dai Wang

IPC分类号： A61K39/395 ,  A61K39/245 ,  G01N33/53 ,  A61P31/22 ,  C07K16/08

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/505 ,  C07K14/005 ,  C07K16/085 ,  C07K16/088 ,  C07K2317/76 ,  C12N7/00 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12Q1/025 ,  G01N2500/04

摘要： Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

摘要翻译： 公开了用于保护和治疗人巨细胞病毒（CMV）的免疫原性组合物和预防或治疗性疫苗。 描述了包含包含pUL128或pUL130的人CMV蛋白复合物的亚单位疫苗和包含至少一种编码包含pUL128或pUL130的CMV蛋白质复合物的核酸的核酸疫苗。 还公开了对包含pUL128或pUL130的CMV蛋白质复合物具有反应性的治疗性抗体以及用于筛选抑制上皮和内皮细胞的CMV感染的化合物的方法，用于免疫CMV感染的受试者的方法，用于测定中和抗体的能力的方法 以抑制除成纤维细胞以外的细胞类型的人CMV感染，以及减少CMV感染的方法。

公开(公告)号：US09439960B2

公开(公告)日：2016-09-13

申请号：US12681504

申请日：2008-10-01

申请人： Thomas Shenk ,  Dai Wang

发明人： Thomas Shenk ,  Dai Wang

IPC分类号： A61K39/245 ,  A61K39/12 ,  A61K39/00

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/54 ,  C12N7/00 ,  C12N2710/16134 ,  C12N2710/16151 ,  C12N2710/16164

摘要： Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed.

摘要翻译： 公开了通过选择扩增病毒的细胞类型增加巨细胞病毒疫苗多样性的方法，以及通过这些方法产生的巨细胞病毒在开发疫苗组合物中的应用。 还公开了包含从上皮细胞分离的CMV的疫苗组合物。